Hormonal Contraceptives Market Report 2026

The hormonal contraceptives market size has grown marginally in recent years. It will grow from $14.4 billion in 2025 to $14.58 billion in 2026 at a compound annual growth rate (CAGR) of 1.2%. The growth in the historic period can be attributed to rising awareness of family planning, introduction of combined oral contraceptives, government initiatives for reproductive health, increasing urbanization, growth of gynecology clinics.

The hormonal contraceptives market size is expected to see steady growth in the next few years. It will grow to $15.82 billion in 2030 at a compound annual growth rate (CAGR) of 2.1%. The growth in the forecast period can be attributed to advancements in personalized hormone therapies, rise of male contraceptive products, expansion of e-commerce for contraceptives, integration of digital health platforms, increasing focus on STD prevention. Major trends in the forecast period include rise of hormone-based personalized contraceptives, increasing awareness of reversible and non-reversible options, growth in telemedicine and online contraceptive services, expansion of male contraceptive solutions, focus on contraceptives with dual protection against stds.

Growing awareness of hormonal contraceptives has led to a more informed and empowered population, enabling individuals to make choices that align with their reproductive goals and lifestyles. As people become more knowledgeable about available contraceptive options, they are better equipped to make decisions regarding their reproductive health, which in turn drives greater adoption of hormonal contraceptives suited to their family planning and lifestyle preferences. For example, in July 2025, according to the World Health Organization (WHO), a Switzerland-based specialized UN agency for international public health, 874 million women were using modern contraceptives, supporting public health, advancing gender equality, strengthening health systems, and promoting economic development. An additional 70 million women are projected to gain access by 2030. This rising awareness of the benefits and use of contraceptives is a significant factor propelling the hormonal contraceptives market.

Rising healthcare expenditure is expected to boost the growth of the hormonal contraceptives market in the coming years. Healthcare expenditure refers to the total financial resources spent by individuals, organizations, or governments on preventing, treating, and managing health conditions. Increasing expenditure is driven by advances in medical technology, as new diagnostic tools, treatments, and therapies often come at higher costs. Higher healthcare spending promotes the use of hormonal contraceptives by improving access, affordability, awareness, and supporting research and family planning programs. For example, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency administering Medicare and Medicaid programs, U.S. healthcare expenditures rose by 7.5% in 2023, reaching $4.9 trillion, or roughly $14,570 per person. Therefore, increasing healthcare expenditure is driving the expansion of the hormonal contraceptives market.

Leading companies in the hormonal contraceptives market are developing innovative products, such as nonprescription daily oral contraceptives, to improve accessibility and convenience for users. A nonprescription daily oral contraceptive is a birth control pill that can be purchased without a prescription from a healthcare provider. For instance, in July 2023, Perrigo Company PLC, a US-based manufacturer of private-label over-the-counter pharmaceuticals, received approval from the Food and Drug Administration (FDA) for Opill. Opill is the first nonprescription daily oral contraceptive, making effective birth control available to consumers without requiring a prescription or a healthcare appointment. This launch represents a significant milestone in reproductive health.

Major companies operating in the hormonal contraceptives market are Bayer AG, Merck & Co. Inc, Viatris, Gedeon Richter, AbbVie, Pfizer, Teva Pharmaceuticals, Mayne Pharma Group Limited, Lupin Limited, HLL Lifecare Limited, Amneal Pharmaceuticals, DKT International, Piramal Pharma Limited, Allergan, Afaxys Inc., Agile Therapeutic, Cipla Limited, Glenmark Pharmaceuticals, Novartis AG, Sun Pharmaceutical Industries Ltd., Apothecus Pharmaceutical Corporation, Famy Care, Mylan Laboratories.

North America was the largest region in the hormonal contraceptives market share in 2025. Middle East is expected to be the fastest-growing region in the global hormonal contraceptives market analysis during the forecast period. The regions covered in the hormonal contraceptives market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hormonal contraceptives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the hormonal contraceptives market by increasing the cost of imported raw materials, active pharmaceutical ingredients, and delivery devices, which has raised production costs for pills, injectable contraceptives, and hormonal implants. Asia-Pacific regions such as India and China, which are major manufacturers, are particularly affected, while hospitals and gynecology centers face higher procurement costs. However, tariffs are also encouraging local production and innovation, potentially reducing dependency on imports and fostering cost-efficient solutions in the long term.

The hormonal contraceptives market research report is one of a series of new reports that provides hormonal contraceptives market statistics, including hormonal contraceptives industry global market size, regional shares, competitors with a hormonal contraceptives market share, detailed hormonal contraceptives market segments, market trends and opportunities, and any further data you may need to thrive in the hormonal contraceptives industry. This hormonal contraceptives market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hormonal contraceptives are birth control methods that prevent pregnancy through the use of hormones. There are various types, some of which are reversible, while others are permanent. Certain forms can also help reduce the risk of STDs.

The main types of products include injectable birth control, emergency contraceptive pills, vaginal rings, and others. Oral contraceptive pills, or birth control pills, consist of synthetic steroid hormones that inhibit the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior pituitary in females. These pills contain different hormones, including progestin-only and combined hormones, and are used in hospitals, homecare settings, gynecology centers, clinics, and ambulatory surgical centers. They are distributed through channels such as drugstores, gynecology or fertility clinics, e-commerce platforms, and others.

The hormonal contraceptive market includes revenues earned by entities by blocking the release of eggs from the ovaries and thinning the lining of the uterus to prevent pregnancy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.